Pluristem Therapeutics Announces Interim Top-Line Results From PLX-PAD Clinical Trials
29-Apr-2010 -
Pluristem Therapeutics Inc. announced interim top-line results from its Phase I clinical trials utilizing its placenta-derived cell therapy product, PLX-PAD, for the treatment of critical limb ischemia (CLI), the end-stage of peripheral artery disease (PAD). The interim data demonstrated that ...
clinical trials
Germany
immunology
+4